Shandong Tumor Hospital

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Lung adenocarcinoma harboring uncommon EGFR exon 19 deletion L747_T751del and in cis K754E mutation: a case report and literature review

E746_A750del, the most common and predominant EGFR exon 19 deletion in non-small cell lung cancer, shows excellent sensitivity to EGFR tyrosine kinase inhibitors. However, other...

Prognostic Impact of TP53 Mutations in Diffuse Large B-Cell Lymphoma

<title>Abstract</title> <bold>Objective:</bold> To evaluate the prognostic value of TP53 mutations in patients with diffuse large B-cell lymphoma (DLBCL). <bold>Methods:</bold> ...

Clinical Significance of Hepatitis A Virus Cellular Receptor 1 (HAVCR-1) in Breast Cancer

<title>Abstract</title> <bold>Background:</bold> Hepatitis A virus cellular receptor 1 (HAVCR-1), first discovered as the entry factor for hepatitis A virus, has since been reco...